Erythrodermic Psoriasis Managed with Risankizumab
Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies. EP is usually a therapeutic challenge, where topical and conventi...
Saved in:
Main Authors: | Abdulmajeed Alajlan (Author), Abdulaziz Madani (Author), Tala Ammar Qadoumi (Author), Alhanouf Aljaloud (Author), Mohammed Alessa (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023) -
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024) -
The Management of Erythrodermic Psoriasis Complicated by Cyclosporine
by: Suman Rao, et al.
Published: (2020) -
Refractory dissecting cellulitis of the scalp treated with risankizumab: 2 case reports
by: Khalid Nabil Nagshabandi, MBBS, et al.
Published: (2023) -
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
by: Potestio L, et al.
Published: (2023)